$DCOY News

DCOY preclinical PK supports once‑weekly intranasal dosing for DCOY‑CoV

Decoy Therapeutics (DCOY) reported preclinical pharmacokinetic data showing a single intranasal dose of its lead candidate DCOY‑CoV maintained drug levels above the company’s designed antiviral concentrations in nasal mucosa and lung tissue for up to seven days. The company says DCOY‑CoV is designed to protect against multiple endemic coronaviruses (including SARS‑CoV‑2) and plans to enter clinical trials in 2027; the data are preclinical and were presented at a peptide symposium.

Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release

Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules

Paid NTHI editorial — market roundup on VKTX, NTHI, DCOY, GRML; no financing announced

24/7 Market News published a paid editorial highlighting Viking Therapeutics (VKTX), NeOnc Technologies (NTHI), Decoy Therapeutics (DCOY) and Greenland Mines (GRML) and discloses that NTHI compensated the publisher for ongoing coverage. The article provides company updates and catalyst commentary but does not announce any securities offering, financing terms, or share issuance.

Decoy (DCOY) pursues pan‑filovirus D‑MAV program via FDA Animal Rule after in‑vitro Ebola/Marburg activity

Decoy (DCOY) said it is advancing a pan‑filovirus Designable Multi‑Antiviral (D‑MAV) program via the FDA Animal Rule pathway while seeking non‑dilutive government grants and public‑health partnerships and targeting Priority Review Voucher (PRV) monetization. A first‑generation de novo candidate showed low‑micromolar IC50 against wild‑type Ebola Zaire (reported >5x potency vs its prior pan‑coronavirus lead and ~7x vs remdesivir) and demonstrated activity against Marburg; the platform is being engineered for extended tissue residence that could support infrequent dosing. All results are preclinical (in vitro) — Decoy has not announced INDs, clinical efficacy data, or secured non‑dilutive funding, and Animal Rule approval would require successful animal efficacy plus human safety/PK data.

Stockholders approve issuance of shares on exercise of Series A‑C 'Milestone' warrants (>=20%); authorized shares cut to 90M

DECOY THERAPEUTICS INC. filed SEC Form 8-K. Shareholders approved the issuance of shares upon exercise of Series A, B and C 'Milestone' warrants issued in a prior private placement — the proposal expressly covers issuance that would equal 20% or more of shares outstanding, creating potential future overhang if warrants are exercised. They also approved an amendment reducing authorized common shares by 10,000,000 to 90,000,000. The filing provides no exercise prices, schedules, or first-possible exercise dates, so any dilution/sell pressure depends on future warrant exercises and timing is undefined.

Decoy (DCOY) expands IP to cover D‐MAVs, manufacturing and IMP3ACT design platform

Decoy Therapeutics (NASDAQ: DCOY) expanded its intellectual property portfolio to seven patent families with one granted U.S. patent and 19 pending applications across seven jurisdictions, covering antiviral peptide conjugates, manufacturing methods, formulations and the IMP3ACT design platform. The granted U.S. patent (No. 12,226,474) claims antiviral peptide conjugates with D‐amino acid viral spike sequences, and a June 2026 filing covers the platform's design methods—strengthening proprietary protection for its Designable Multi‐Antivirals while most applications remain pending.

Decoy Therapeutics (DCOY) elects ex‐Moderna leader Patricia Gauthier to board

Decoy Therapeutics (NASDAQ: DCOY) said stockholders elected Patricia Gauthier, former Moderna SVP and ex‐GSK leader, as a Class II director at its July 14, 2026 annual meeting. The company says her commercialization, manufacturing and market‐access experience will help advance Decoy's Designable Multi‐Antiviral (D‐MAV) programs toward the clinic.

DCOY private placement: initial ~$3.5M, up to ~$21M via milestone-tied warrant exercises

Decoy Therapeutics (DCOY) announced a private placement with a healthcare-focused institutional investor that could provide up to approximately $21M total: an expected initial closing of about $3.5M in gross proceeds and additional funding tied to milestone-based warrant exercises. Initial dilution will occur at the initial closing (≈$3.5M); further dilution is contingent on specified clinical and regulatory milestones (European CTA, UK Phase 2a approval, positive human challenge data) and related warrant issuance/exercise. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.

DCOY inks private placement up to ~$21M; initial close ~ $3.5M, milestone warrants

Decoy Therapeutics (DCOY) announced a private placement with a healthcare-focused institutional investor that could deliver up to approximately $21 million via upfront proceeds plus milestone-tied warrant exercises. The initial closing is expected to generate about $3.5 million in gross proceeds and additional tranches hinge on regulatory/clinical milestones (EU clinical trial authorization, UK Phase 2a approval, positive human challenge data), so further dilution is conditional on those triggers. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.

DCOY CEO to speak at hVIVO Capital Markets Day in London

Decoy Therapeutics (DCOY) said CEO Rick Pierce will speak at hVIVO's Capital Markets Day in London on June 11 to discuss early clinical development and the strategic value of human challenge trials. The company reiterated its AI-enabled IMP3ACT platform and a pan-coronavirus D-MAV program targeting clinic entry in 2027 — the update raises investor visibility but includes no new clinical data or filings.

Decoy (DCOY) partners with hVIVO to advance lead D‐MAV toward Phase 1/2a and human challenge studies

Decoy Therapeutics (DCOY) has engaged hVIVO to support translational modeling, regulatory strategy, CMC/nonclinical consulting and preparation for Phase 1 first‐in‐human and Phase 2a proof‐of‐concept studies for its lead D‐MAV respiratory antiviral, with planned regulatory interactions in the EU/UK and intent to pursue US registration. hVIVO's human challenge trial expertise and facilities are expected to inform dose selection and study design and create a repeatable clinical template for Decoy's D‐MAV portfolio, but the program is still preclinical and no IND/CTA has been filed.